CGON Stock Overview
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CG Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$39.50 |
| 52 Week High | US$50.23 |
| 52 Week Low | US$28.55 |
| Beta | 0 |
| 1 Month Change | -2.47% |
| 3 Month Change | 10.30% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| CGON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.1% | 2.7% | 0.3% |
| 1Y | n/a | 2.9% | 24.2% |
Return vs Industry: Insufficient data to determine how CGON performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CGON performed against the US Market.
Price Volatility
| CGON volatility | |
|---|---|
| CGON Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CGON has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CGON's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 61 | Arthur Kuan | cgoncology.com |
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
CG Oncology, Inc. Fundamentals Summary
| CGON fundamental statistics | |
|---|---|
| Market cap | US$2.71b |
| Earnings (TTM) | -US$67.80m |
| Revenue (TTM) | US$204.00k |
Over9,999x
P/S Ratio-38.8x
P/E RatioIs CGON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGON income statement (TTM) | |
|---|---|
| Revenue | US$204.00k |
| Cost of Revenue | US$45.75m |
| Gross Profit | -US$45.55m |
| Other Expenses | US$22.25m |
| Earnings | -US$67.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | -22,327.45% |
| Net Profit Margin | -33,234.31% |
| Debt/Equity Ratio | 0% |
How did CGON perform over the long term?
See historical performance and comparison